Revisiting the dose constraints for head and neck OARs in the current era of IMRT

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Head and neck cancer poses a particular challenge in radiation therapy, whilst being an effective treatment modality it requires very high doses of radiation to provide effective therapy. This is further complicated by the fact that the head and neck region contains a large number of radiosensitive tissues, often resulting in patients experiencing debilitating normal tissue complications. In the era of intensity-modulated radiation therapy (IMRT) treatments can be delivered using non-uniform dose distributions selectively aimed at reducing the dose to critical organs-at-risk while still adequately covering the tumor target. Dose-volume constraints for the different risk organs play a vital role in one's ability to devise the best IMRT treatment plan for a head and neck cancer patient. To this end, it is pivotal to have access to the latest and most relevant dose constraints available and as such the goal of this review is to provide a summary of suggested dose-volume constraints for head and neck cancer RT that have been published after the QUANTEC reports were made available in early 2010.

Original languageEnglish (US)
Pages (from-to)8-18
Number of pages11
JournalOral Oncology
Volume86
DOIs
StatePublished - Nov 1 2018

Fingerprint

Neck
Radiotherapy
Head and Neck Neoplasms
Head
Organs at Risk
Therapeutics
Radiation
Neoplasms

Keywords

  • Dose constraints
  • Dose objectives
  • Head and neck
  • IMRT
  • Organs at risk

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

Revisiting the dose constraints for head and neck OARs in the current era of IMRT. / Brodin, Nils P.; Tome, Wolfgang A.

In: Oral Oncology, Vol. 86, 01.11.2018, p. 8-18.

Research output: Contribution to journalArticle

@article{18393bd6e6864794a6cd105bb6a4bfd1,
title = "Revisiting the dose constraints for head and neck OARs in the current era of IMRT",
abstract = "Head and neck cancer poses a particular challenge in radiation therapy, whilst being an effective treatment modality it requires very high doses of radiation to provide effective therapy. This is further complicated by the fact that the head and neck region contains a large number of radiosensitive tissues, often resulting in patients experiencing debilitating normal tissue complications. In the era of intensity-modulated radiation therapy (IMRT) treatments can be delivered using non-uniform dose distributions selectively aimed at reducing the dose to critical organs-at-risk while still adequately covering the tumor target. Dose-volume constraints for the different risk organs play a vital role in one's ability to devise the best IMRT treatment plan for a head and neck cancer patient. To this end, it is pivotal to have access to the latest and most relevant dose constraints available and as such the goal of this review is to provide a summary of suggested dose-volume constraints for head and neck cancer RT that have been published after the QUANTEC reports were made available in early 2010.",
keywords = "Dose constraints, Dose objectives, Head and neck, IMRT, Organs at risk",
author = "Brodin, {Nils P.} and Tome, {Wolfgang A.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.oraloncology.2018.08.018",
language = "English (US)",
volume = "86",
pages = "8--18",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Revisiting the dose constraints for head and neck OARs in the current era of IMRT

AU - Brodin, Nils P.

AU - Tome, Wolfgang A.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Head and neck cancer poses a particular challenge in radiation therapy, whilst being an effective treatment modality it requires very high doses of radiation to provide effective therapy. This is further complicated by the fact that the head and neck region contains a large number of radiosensitive tissues, often resulting in patients experiencing debilitating normal tissue complications. In the era of intensity-modulated radiation therapy (IMRT) treatments can be delivered using non-uniform dose distributions selectively aimed at reducing the dose to critical organs-at-risk while still adequately covering the tumor target. Dose-volume constraints for the different risk organs play a vital role in one's ability to devise the best IMRT treatment plan for a head and neck cancer patient. To this end, it is pivotal to have access to the latest and most relevant dose constraints available and as such the goal of this review is to provide a summary of suggested dose-volume constraints for head and neck cancer RT that have been published after the QUANTEC reports were made available in early 2010.

AB - Head and neck cancer poses a particular challenge in radiation therapy, whilst being an effective treatment modality it requires very high doses of radiation to provide effective therapy. This is further complicated by the fact that the head and neck region contains a large number of radiosensitive tissues, often resulting in patients experiencing debilitating normal tissue complications. In the era of intensity-modulated radiation therapy (IMRT) treatments can be delivered using non-uniform dose distributions selectively aimed at reducing the dose to critical organs-at-risk while still adequately covering the tumor target. Dose-volume constraints for the different risk organs play a vital role in one's ability to devise the best IMRT treatment plan for a head and neck cancer patient. To this end, it is pivotal to have access to the latest and most relevant dose constraints available and as such the goal of this review is to provide a summary of suggested dose-volume constraints for head and neck cancer RT that have been published after the QUANTEC reports were made available in early 2010.

KW - Dose constraints

KW - Dose objectives

KW - Head and neck

KW - IMRT

KW - Organs at risk

UR - http://www.scopus.com/inward/record.url?scp=85052966795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052966795&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2018.08.018

DO - 10.1016/j.oraloncology.2018.08.018

M3 - Article

C2 - 30409324

AN - SCOPUS:85052966795

VL - 86

SP - 8

EP - 18

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

ER -